Bone Marrow Transplantation for Chronic Myeloid Leukemia in France. Results of the French Cooperative Group View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1993

AUTHORS

A. Devergie , J. Reiffers , J. P. Vernant , P. Hérvé , D. Guyotat , D. Maraninchi , M. Michallet , B. Rio , J. P. Jouet , P. Lehn , E. Gluckman

ABSTRACT

Transplants were performed in 281 patients (pts) with chronic myeloid leukemia (CML) in France between 1979 and 1986. The actuarial survival after 5 years is 55% for the patients receiving grafts in first chronic phase (CP), 43% for the patients given grafts in accelerated phase (AP) or second CP, and 35% for the patients receiving grafts in blastic crisis (BC). The main cause of death was interstitial pneumonitis and/or acute graft-versus-host disease (AGVHD). The incidence of AGVHD appears correlated with prophylactic treatment: 58% after methotrexate alone (MTX), 41% after cyclosporine (CSA), 26% after MTX + CSA, and only 14% after T-cell depletion. On the contrary, the relapse rate was much higher after T-cell depletion or syngeneic bone marrow transplantation (BMT) (70%) than after allogeneic non-T-cell-depleted BMT (18%). In this last group of patients, the relapse rate is correlated with the phase of CML at time of BMT: 10% for 102 patients in first CP and 30% for 77 patients in more advanced disease. Finally, the incidence of long-term disease-free survival is 55% for patients receiving grafts in first CP with a non-T-cell-depleted marrow. We conclude that the probability of cure after allogeneic BMT is very high, especially for patients in CP receiving non-T-cell-depleted marrow. More... »

PAGES

193-193

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-77083-8_35

DOI

http://dx.doi.org/10.1007/978-3-642-77083-8_35

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1028108759


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "GEGMO, UFGM, H\u00f4pital Saint-Louis, 1 av. Claude Vellefaux, 75475, Paris Cedex, France", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "GEGMO, UFGM, H\u00f4pital Saint-Louis, 1 av. Claude Vellefaux, 75475, Paris Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Devergie", 
        "givenName": "A.", 
        "id": "sg:person.01030157062.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030157062.20"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Reiffers", 
        "givenName": "J.", 
        "id": "sg:person.01230203137.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230203137.18"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Vernant", 
        "givenName": "J. P.", 
        "id": "sg:person.01035473414.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035473414.57"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "H\u00e9rv\u00e9", 
        "givenName": "P.", 
        "id": "sg:person.01370064012.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370064012.69"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Guyotat", 
        "givenName": "D.", 
        "id": "sg:person.0655776276.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655776276.35"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Maraninchi", 
        "givenName": "D.", 
        "id": "sg:person.01364057057.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364057057.31"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Michallet", 
        "givenName": "M.", 
        "id": "sg:person.01264301106.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264301106.83"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Rio", 
        "givenName": "B.", 
        "id": "sg:person.01245127334.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245127334.86"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Jouet", 
        "givenName": "J. P.", 
        "id": "sg:person.01217040576.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217040576.37"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Lehn", 
        "givenName": "P.", 
        "id": "sg:person.01362751275.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362751275.10"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Gluckman", 
        "givenName": "E.", 
        "id": "sg:person.01344451445.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344451445.17"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1993", 
    "datePublishedReg": "1993-01-01", 
    "description": "Transplants were performed in 281 patients (pts) with chronic myeloid leukemia (CML) in France between 1979 and 1986. The actuarial survival after 5 years is 55% for the patients receiving grafts in first chronic phase (CP), 43% for the patients given grafts in accelerated phase (AP) or second CP, and 35% for the patients receiving grafts in blastic crisis (BC). The main cause of death was interstitial pneumonitis and/or acute graft-versus-host disease (AGVHD). The incidence of AGVHD appears correlated with prophylactic treatment: 58% after methotrexate alone (MTX), 41% after cyclosporine (CSA), 26% after MTX + CSA, and only 14% after T-cell depletion. On the contrary, the relapse rate was much higher after T-cell depletion or syngeneic bone marrow transplantation (BMT) (70%) than after allogeneic non-T-cell-depleted BMT (18%). In this last group of patients, the relapse rate is correlated with the phase of CML at time of BMT: 10% for 102 patients in first CP and 30% for 77 patients in more advanced disease. Finally, the incidence of long-term disease-free survival is 55% for patients receiving grafts in first CP with a non-T-cell-depleted marrow. We conclude that the probability of cure after allogeneic BMT is very high, especially for patients in CP receiving non-T-cell-depleted marrow.", 
    "editor": [
      {
        "familyName": "Fleischer", 
        "givenName": "J.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-77083-8_35", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-642-77085-2", 
        "978-3-642-77083-8"
      ], 
      "name": "Leukemias", 
      "type": "Book"
    }, 
    "keywords": [
      "bone marrow transplantation", 
      "chronic myeloid leukemia", 
      "first chronic phase", 
      "T-cell depletion", 
      "chronic phase", 
      "relapse rate", 
      "marrow transplantation", 
      "blastic crisis", 
      "myeloid leukemia", 
      "phases of CML", 
      "long-term disease-free survival", 
      "time of BMT", 
      "syngeneic bone marrow transplantation", 
      "allogeneic bone marrow transplantation", 
      "accelerated phase", 
      "incidence of aGVHD", 
      "second chronic phase", 
      "disease-free survival", 
      "French Cooperative Group", 
      "probability of cure", 
      "actuarial survival", 
      "acute graft", 
      "interstitial pneumonitis", 
      "host disease", 
      "advanced disease", 
      "prophylactic treatment", 
      "patients", 
      "graft", 
      "cooperative groups", 
      "transplantation", 
      "leukemia", 
      "marrow", 
      "disease", 
      "incidence", 
      "last group", 
      "survival", 
      "main cause", 
      "aGVHD", 
      "pneumonitis", 
      "cyclosporine", 
      "transplant", 
      "group", 
      "methotrexate", 
      "MTX", 
      "death", 
      "CsA", 
      "cure", 
      "depletion", 
      "treatment", 
      "cause", 
      "rate", 
      "years", 
      "France", 
      "time", 
      "phase", 
      "contrary", 
      "results", 
      "probability", 
      "crisis"
    ], 
    "name": "Bone Marrow Transplantation for Chronic Myeloid Leukemia in France. Results of the French Cooperative Group", 
    "pagination": "193-193", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1028108759"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-77083-8_35"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-77083-8_35", 
      "https://app.dimensions.ai/details/publication/pub.1028108759"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-10-01T06:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/chapter/chapter_304.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-77083-8_35"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-77083-8_35'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-77083-8_35'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-77083-8_35'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-77083-8_35'


 

This table displays all metadata directly associated to this object as RDF triples.

178 TRIPLES      22 PREDICATES      84 URIs      77 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-77083-8_35 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Na76c67b2fb5048188967fbd7a54f00cb
4 schema:datePublished 1993
5 schema:datePublishedReg 1993-01-01
6 schema:description Transplants were performed in 281 patients (pts) with chronic myeloid leukemia (CML) in France between 1979 and 1986. The actuarial survival after 5 years is 55% for the patients receiving grafts in first chronic phase (CP), 43% for the patients given grafts in accelerated phase (AP) or second CP, and 35% for the patients receiving grafts in blastic crisis (BC). The main cause of death was interstitial pneumonitis and/or acute graft-versus-host disease (AGVHD). The incidence of AGVHD appears correlated with prophylactic treatment: 58% after methotrexate alone (MTX), 41% after cyclosporine (CSA), 26% after MTX + CSA, and only 14% after T-cell depletion. On the contrary, the relapse rate was much higher after T-cell depletion or syngeneic bone marrow transplantation (BMT) (70%) than after allogeneic non-T-cell-depleted BMT (18%). In this last group of patients, the relapse rate is correlated with the phase of CML at time of BMT: 10% for 102 patients in first CP and 30% for 77 patients in more advanced disease. Finally, the incidence of long-term disease-free survival is 55% for patients receiving grafts in first CP with a non-T-cell-depleted marrow. We conclude that the probability of cure after allogeneic BMT is very high, especially for patients in CP receiving non-T-cell-depleted marrow.
7 schema:editor N6559ab3b3c51464c8a39a50a41a1cc7f
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N91d900173b7e48bc8cd31d111fad113b
11 schema:keywords CsA
12 France
13 French Cooperative Group
14 MTX
15 T-cell depletion
16 aGVHD
17 accelerated phase
18 actuarial survival
19 acute graft
20 advanced disease
21 allogeneic bone marrow transplantation
22 blastic crisis
23 bone marrow transplantation
24 cause
25 chronic myeloid leukemia
26 chronic phase
27 contrary
28 cooperative groups
29 crisis
30 cure
31 cyclosporine
32 death
33 depletion
34 disease
35 disease-free survival
36 first chronic phase
37 graft
38 group
39 host disease
40 incidence
41 incidence of aGVHD
42 interstitial pneumonitis
43 last group
44 leukemia
45 long-term disease-free survival
46 main cause
47 marrow
48 marrow transplantation
49 methotrexate
50 myeloid leukemia
51 patients
52 phase
53 phases of CML
54 pneumonitis
55 probability
56 probability of cure
57 prophylactic treatment
58 rate
59 relapse rate
60 results
61 second chronic phase
62 survival
63 syngeneic bone marrow transplantation
64 time
65 time of BMT
66 transplant
67 transplantation
68 treatment
69 years
70 schema:name Bone Marrow Transplantation for Chronic Myeloid Leukemia in France. Results of the French Cooperative Group
71 schema:pagination 193-193
72 schema:productId N860a95ec3d354cc6b5fc9332f006568e
73 Nc15e1eae4635454890fa1fd1677f1ac6
74 schema:publisher N3c39287cbe494226a1fe8a0ec626b64a
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028108759
76 https://doi.org/10.1007/978-3-642-77083-8_35
77 schema:sdDatePublished 2022-10-01T06:56
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher Nca1e81220e5b4757947c48e1d7ac21da
80 schema:url https://doi.org/10.1007/978-3-642-77083-8_35
81 sgo:license sg:explorer/license/
82 sgo:sdDataset chapters
83 rdf:type schema:Chapter
84 N0614799e4bab4923a16aaf11c137b1c7 rdf:first sg:person.01217040576.37
85 rdf:rest N0c035c50af914f2c8a4ae7414a74083c
86 N0c035c50af914f2c8a4ae7414a74083c rdf:first sg:person.01362751275.10
87 rdf:rest N508623ce0220453fad303afeb4b6b24b
88 N38853dccbb804c2ba2e2746fd5a72263 rdf:first sg:person.01245127334.86
89 rdf:rest N0614799e4bab4923a16aaf11c137b1c7
90 N3c39287cbe494226a1fe8a0ec626b64a schema:name Springer Nature
91 rdf:type schema:Organisation
92 N42c3df09c7f6456ab9bbfc38ee4e8682 rdf:first sg:person.0655776276.35
93 rdf:rest Nd3b58d2cd5b3437e9dc38a9f93a14dac
94 N508623ce0220453fad303afeb4b6b24b rdf:first sg:person.01344451445.17
95 rdf:rest rdf:nil
96 N5dd59fae4939441d96b60519d413f5e4 rdf:first sg:person.01264301106.83
97 rdf:rest N38853dccbb804c2ba2e2746fd5a72263
98 N6559ab3b3c51464c8a39a50a41a1cc7f rdf:first Ne6843650440a42de9fd1622e48fb89ab
99 rdf:rest rdf:nil
100 N860a95ec3d354cc6b5fc9332f006568e schema:name doi
101 schema:value 10.1007/978-3-642-77083-8_35
102 rdf:type schema:PropertyValue
103 N91d900173b7e48bc8cd31d111fad113b schema:isbn 978-3-642-77083-8
104 978-3-642-77085-2
105 schema:name Leukemias
106 rdf:type schema:Book
107 Na76c67b2fb5048188967fbd7a54f00cb rdf:first sg:person.01030157062.20
108 rdf:rest Nbdc5e7bf601e4c13b0da733d5dc586f3
109 Nbdc5e7bf601e4c13b0da733d5dc586f3 rdf:first sg:person.01230203137.18
110 rdf:rest Ndf78b046f9894a97962bfbe07c0c2ca1
111 Nc0697d2cf0194d2181145e9adc4c3901 rdf:first sg:person.01370064012.69
112 rdf:rest N42c3df09c7f6456ab9bbfc38ee4e8682
113 Nc15e1eae4635454890fa1fd1677f1ac6 schema:name dimensions_id
114 schema:value pub.1028108759
115 rdf:type schema:PropertyValue
116 Nca1e81220e5b4757947c48e1d7ac21da schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 Nd3b58d2cd5b3437e9dc38a9f93a14dac rdf:first sg:person.01364057057.31
119 rdf:rest N5dd59fae4939441d96b60519d413f5e4
120 Ndf78b046f9894a97962bfbe07c0c2ca1 rdf:first sg:person.01035473414.57
121 rdf:rest Nc0697d2cf0194d2181145e9adc4c3901
122 Ne6843650440a42de9fd1622e48fb89ab schema:familyName Fleischer
123 schema:givenName J.
124 rdf:type schema:Person
125 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
126 schema:name Medical and Health Sciences
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
129 schema:name Oncology and Carcinogenesis
130 rdf:type schema:DefinedTerm
131 sg:person.01030157062.20 schema:affiliation grid-institutes:grid.413328.f
132 schema:familyName Devergie
133 schema:givenName A.
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030157062.20
135 rdf:type schema:Person
136 sg:person.01035473414.57 schema:familyName Vernant
137 schema:givenName J. P.
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035473414.57
139 rdf:type schema:Person
140 sg:person.01217040576.37 schema:familyName Jouet
141 schema:givenName J. P.
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217040576.37
143 rdf:type schema:Person
144 sg:person.01230203137.18 schema:familyName Reiffers
145 schema:givenName J.
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230203137.18
147 rdf:type schema:Person
148 sg:person.01245127334.86 schema:familyName Rio
149 schema:givenName B.
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245127334.86
151 rdf:type schema:Person
152 sg:person.01264301106.83 schema:familyName Michallet
153 schema:givenName M.
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264301106.83
155 rdf:type schema:Person
156 sg:person.01344451445.17 schema:familyName Gluckman
157 schema:givenName E.
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344451445.17
159 rdf:type schema:Person
160 sg:person.01362751275.10 schema:familyName Lehn
161 schema:givenName P.
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362751275.10
163 rdf:type schema:Person
164 sg:person.01364057057.31 schema:familyName Maraninchi
165 schema:givenName D.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364057057.31
167 rdf:type schema:Person
168 sg:person.01370064012.69 schema:familyName Hérvé
169 schema:givenName P.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01370064012.69
171 rdf:type schema:Person
172 sg:person.0655776276.35 schema:familyName Guyotat
173 schema:givenName D.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655776276.35
175 rdf:type schema:Person
176 grid-institutes:grid.413328.f schema:alternateName GEGMO, UFGM, Hôpital Saint-Louis, 1 av. Claude Vellefaux, 75475, Paris Cedex, France
177 schema:name GEGMO, UFGM, Hôpital Saint-Louis, 1 av. Claude Vellefaux, 75475, Paris Cedex, France
178 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...